16,600 Shares of Xencor, Inc. $XNCR Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Xencor, Inc. (NASDAQ:XNCR) during the third quarter, HoldingsChannel reports. The firm acquired 16,600 shares of the biopharmaceutical company’s stock, valued at approximately $414,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Xencor by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,567 shares of the biopharmaceutical company’s stock valued at $339,000 after acquiring an additional 1,767 shares during the period. Pinnacle Wealth Planning Services Inc. boosted its position in Xencor by 31.0% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 5,804 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 1,373 shares during the period. VestGen Advisors LLC purchased a new stake in Xencor during the 3rd quarter worth $2,547,000. GAMMA Investing LLC increased its holdings in Xencor by 15.5% in the 3rd quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 572 shares in the last quarter. Finally, WINTON GROUP Ltd increased its holdings in Xencor by 1.5% in the 2nd quarter. WINTON GROUP Ltd now owns 106,247 shares of the biopharmaceutical company’s stock valued at $1,711,000 after purchasing an additional 1,534 shares in the last quarter.

Xencor Trading Up 5.0%

NASDAQ XNCR opened at $35.75 on Friday. The company’s fifty day simple moving average is $26.17 and its 200-day simple moving average is $17.46. Xencor, Inc. has a 52 week low of $10.38 and a 52 week high of $36.50. The stock has a market cap of $2.68 billion, a P/E ratio of -22.48 and a beta of 0.78.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.83. The business had revenue of $116.52 million during the quarter, compared to the consensus estimate of $63.00 million. Xencor had a negative net margin of 58.79% and a negative return on equity of 21.28%. The business’s quarterly revenue was up 453.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.08) earnings per share. On average, research analysts expect that Xencor, Inc. will post -2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on XNCR. Bank of America raised their price objective on Xencor from $20.00 to $26.00 and gave the company a “neutral” rating in a research report on Monday, September 21st. Wall Street Zen raised Xencor from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research report on Monday, September 21st. JPMorgan Chase & Co. increased their target price on Xencor from $14.00 to $21.00 and gave the company a “neutral” rating in a research note on Thursday, September 3rd. Finally, Wells Fargo & Company raised their target price on Xencor from $30.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $42.22.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.